Assertio Holdings Lawsuit Submission Form

The filed complaint alleges that Assertio Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) Assertio's acquisition of Spectrum Pharmaceuticals, Inc. and Spectrum’s injection asset, Rolvedon, was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the acquisition were likely to have on the Company’s profitability; and (iv) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.